Brean Capital Cuts Price Target After Horizon Pharma (HZNP) Releases Soft Guidance
Tweet Send to a Friend
Brean Capital maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $30.00 (from $32.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
